




R[evolution]

30 Years of Leadership in Biotechnology



2008
Annual Report



Report Junction.com



Above: Panoramic view of Biocon Park

Biocon Corporate Communications | **tsk DESIGN** info@tsk-design.com
Photography: Senthil Mallikarjun Katakol Ryan Lobo

INDIA'S BIOTECH INDUSTRY BEGAN IN 1978 WITH A START-UP – BIOCON. TODAY, MORE THAN 350 COMPANIES PROJECT INDIA AS A LEADING BIOTECH PLAYER.

Report  Junction.com



Above left (B&W): Kiran at a business meeting, 1979

Above right (B&W): Inauguration of Biocon at Hosur Road, 1983

1994

1998

2002

2004

2008

BIOCON'S EVOLUTION INDIA'S BIOREVOLUTION

In 1978, Biocon took the path less traveled to enter the challenging field of biotechnology. The next decade saw the Indian biotech sector take shape and Biocon mature into a global player in industrial enzymes. By the year 2000, Biocon was ready to undergo a metamorphosis into a new age biopharmaceuticals company by leveraging its fermentation technology platform to develop a range of generic pharmaceutical molecules including statins, immunosuppressants and insulin.

With the new millennium came the sequencing of the human genome. This milestone achievement catapulted worldwide interest in biotechnology and attracted considerable investment into the sector. Seizing opportunity, Biocon leveraged important internal synergies to drive its transformation into an integrated biopharmaceuticals enterprise with businesses across the entire drug value chain – from custom & clinical research (Syngene & Clinigene) to manufacturing, development and commercialization. In the external dimension, Biocon entered into symbiotic partnerships with global pharma and biotech companies to rapidly co-develop proprietary products and enter high growth markets.

The promise of biopharmaceuticals has given patients all over the world new hope to treat the most debilitating diseases. Yet the vaulting cost of R&D continues to make these vital drugs prohibitively expensive. Global pressure to bring down the cost of innovation has put the spotlight back on India and Biocon's commitment to affordable new medicine. BIOMAb EGFR™, a novel anti-cancer drug, developed and commercialized by Biocon in 2006, is testimony to Biocon's ability to execute an India strategy for the development of novel therapies.

Today, Biocon is a leading biopharmaceuticals major that proudly projects India's contribution to the global biorevolution. To have achieved this in three decades is reason to celebrate.



Biocon began operations in a small garage in Bangalore. Today, we are Asia's largest biotech company.

FROM MODEST BEGINNINGS, INDIA'S BIOTECH SECTOR NOW ATTRACTS OVER A BILLION DOLLARS IN INVESTMENTS.

Report Junction.com



Above left (B&W): Isinglass Processing, 1980

Above right (B&W): Enzyme Plant, 1990



From a seed investment of Rs.10,000,
Biocon listed as a billion dollar
market cap company in 2004.

THREE DECADES AGO, INDIAN SCIENTISTS AND ENGINEERS WERE HEADED OVERSEAS FOR OPPORTUNITIES IN BIOTECHNOLOGY. TODAY, INDIA IS A COVETED BIOTECH DESTINATION THAT WILL EMPLOY OVER A MILLION PEOPLE BY 2010.

ReportJunction.com



Above (B&W): Kiran at the Biocon building site, 1982



In 1978, a woman entrepreneur with a pioneering vision created Biocon. Today, a 3,500-strong team propels it into the future.

LEVERAGING ITS COST ARBITRAGE, INDIA'S BIOTECH SECTOR DELIVERS HIGH VALUE INNOVATION IN DRUG DEVELOPMENT AND GLOBAL COMPETITIVENESS IN BIOMANUFACTURING (IT IS TODAY THE LARGEST VACCINE PRODUCER IN THE WORLD).



Above left (B&W): RK Hedge, Former Chief Minister, Karnataka inaugurates Biocon's enzyme fermenter, 1990

Above right (B&W): Visitors at the 2nd solid state fermentation plant for enzymes and statins, 1996